280 related articles for article (PubMed ID: 18627596)
1. The function of BCL9 in Wnt/beta-catenin signaling and colorectal cancer cells.
de la Roche M; Worm J; Bienz M
BMC Cancer; 2008 Jul; 8():199. PubMed ID: 18627596
[TBL] [Abstract][Full Text] [Related]
2. BCL9-2 binds Arm/beta-catenin in a Tyr142-independent manner and requires Pygopus for its function in Wg/Wnt signaling.
Hoffmans R; Basler K
Mech Dev; 2007 Jan; 124(1):59-67. PubMed ID: 17113272
[TBL] [Abstract][Full Text] [Related]
3. Role of a BCL9-related beta-catenin-binding protein, B9L, in tumorigenesis induced by aberrant activation of Wnt signaling.
Adachi S; Jigami T; Yasui T; Nakano T; Ohwada S; Omori Y; Sugano S; Ohkawara B; Shibuya H; Nakamura T; Akiyama T
Cancer Res; 2004 Dec; 64(23):8496-501. PubMed ID: 15574752
[TBL] [Abstract][Full Text] [Related]
4. LEF1 and B9L shield β-catenin from inactivation by Axin, desensitizing colorectal cancer cells to tankyrase inhibitors.
de la Roche M; Ibrahim AE; Mieszczanek J; Bienz M
Cancer Res; 2014 Mar; 74(5):1495-505. PubMed ID: 24419084
[TBL] [Abstract][Full Text] [Related]
5. BCL9 Upregulation in Adrenocortical Carcinoma: A Novel Wnt/β-Catenin Activating Event Driving Adrenocortical Malignancy.
Brown TC; Nicolson NG; Korah R; Carling T
J Am Coll Surg; 2018 Jun; 226(6):988-995. PubMed ID: 29428231
[TBL] [Abstract][Full Text] [Related]
6. BCL9-2 promotes early stages of intestinal tumor progression.
Brembeck FH; Wiese M; Zatula N; Grigoryan T; Dai Y; Fritzmann J; Birchmeier W
Gastroenterology; 2011 Oct; 141(4):1359-70, 1370.e1-3. PubMed ID: 21703997
[TBL] [Abstract][Full Text] [Related]
7. BCL9 is an essential component of canonical Wnt signaling that mediates the differentiation of myogenic progenitors during muscle regeneration.
Brack AS; Murphy-Seiler F; Hanifi J; Deka J; Eyckerman S; Keller C; Aguet M; Rando TA
Dev Biol; 2009 Nov; 335(1):93-105. PubMed ID: 19699733
[TBL] [Abstract][Full Text] [Related]
8. Cell-type-specific function of BCL9 involves a transcriptional activation domain that synergizes with beta-catenin.
Sustmann C; Flach H; Ebert H; Eastman Q; Grosschedl R
Mol Cell Biol; 2008 May; 28(10):3526-37. PubMed ID: 18347063
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis of β-catenin target genes in colorectal carcinoma cell lines with deregulated Wnt/β-catenin signaling.
Herbst A; Jurinovic V; Krebs S; Thieme SE; Blum H; Göke B; Kolligs FT
BMC Genomics; 2014 Jan; 15():74. PubMed ID: 24467841
[TBL] [Abstract][Full Text] [Related]
10. Constitutive scaffolding of multiple Wnt enhanceosome components by Legless/BCL9.
van Tienen LM; Mieszczanek J; Fiedler M; Rutherford TJ; Bienz M
Elife; 2017 Mar; 6():. PubMed ID: 28296634
[TBL] [Abstract][Full Text] [Related]
11. Maintenance of adenomatous polyposis coli (APC)-mutant colorectal cancer is dependent on Wnt/beta-catenin signaling.
Scholer-Dahirel A; Schlabach MR; Loo A; Bagdasarian L; Meyer R; Guo R; Woolfenden S; Yu KK; Markovits J; Killary K; Sonkin D; Yao YM; Warmuth M; Sellers WR; Schlegel R; Stegmeier F; Mosher RE; McLaughlin ME
Proc Natl Acad Sci U S A; 2011 Oct; 108(41):17135-40. PubMed ID: 21949247
[TBL] [Abstract][Full Text] [Related]
12. LATS2 suppresses oncogenic Wnt signaling by disrupting β-catenin/BCL9 interaction.
Li J; Chen X; Ding X; Cheng Y; Zhao B; Lai ZC; Al Hezaimi K; Hakem R; Guan KL; Wang CY
Cell Rep; 2013 Dec; 5(6):1650-63. PubMed ID: 24360964
[TBL] [Abstract][Full Text] [Related]
13. Fusion of the BCL9 HD2 domain to E1A increases the cytopathic effect of an oncolytic adenovirus that targets colon cancer cells.
Fuerer C; Homicsko K; Lukashev AN; Pittet AL; Iggo RD
BMC Cancer; 2006 Oct; 6():236. PubMed ID: 17020613
[TBL] [Abstract][Full Text] [Related]
14. BCL9/9L-β-catenin Signaling is Associated With Poor Outcome in Colorectal Cancer.
Moor AE; Anderle P; Cantù C; Rodriguez P; Wiedemann N; Baruthio F; Deka J; André S; Valenta T; Moor MB; Győrffy B; Barras D; Delorenzi M; Basler K; Aguet M
EBioMedicine; 2015 Dec; 2(12):1932-43. PubMed ID: 26844272
[TBL] [Abstract][Full Text] [Related]
15. Loss of BCL9/9l suppresses Wnt driven tumourigenesis in models that recapitulate human cancer.
Gay DM; Ridgway RA; Müller M; Hodder MC; Hedley A; Clark W; Leach JD; Jackstadt R; Nixon C; Huels DJ; Campbell AD; Bird TG; Sansom OJ
Nat Commun; 2019 Feb; 10(1):723. PubMed ID: 30760720
[TBL] [Abstract][Full Text] [Related]
16. Targeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling.
Takada K; Zhu D; Bird GH; Sukhdeo K; Zhao JJ; Mani M; Lemieux M; Carrasco DE; Ryan J; Horst D; Fulciniti M; Munshi NC; Xu W; Kung AL; Shivdasani RA; Walensky LD; Carrasco DR
Sci Transl Med; 2012 Aug; 4(148):148ra117. PubMed ID: 22914623
[TBL] [Abstract][Full Text] [Related]
17. The interactions of Bcl9/Bcl9L with β-catenin and Pygopus promote breast cancer growth, invasion, and metastasis.
Vafaizadeh V; Buechel D; Rubinstein N; Kalathur RKR; Bazzani L; Saxena M; Valenta T; Hausmann G; Cantù C; Basler K; Christofori G
Oncogene; 2021 Oct; 40(43):6195-6209. PubMed ID: 34545187
[TBL] [Abstract][Full Text] [Related]
18. Wnt status-dependent oncogenic role of BCL9 and BCL9L in hepatocellular carcinoma.
Huge N; Sandbothe M; Schröder AK; Stalke A; Eilers M; Schäffer V; Schlegelberger B; Illig T; Vajen B; Skawran B
Hepatol Int; 2020 May; 14(3):373-384. PubMed ID: 31440992
[TBL] [Abstract][Full Text] [Related]
19. Involvement of splicing factor-1 in beta-catenin/T-cell factor-4-mediated gene transactivation and pre-mRNA splicing.
Shitashige M; Naishiro Y; Idogawa M; Honda K; Ono M; Hirohashi S; Yamada T
Gastroenterology; 2007 Mar; 132(3):1039-54. PubMed ID: 17383426
[TBL] [Abstract][Full Text] [Related]
20. A coactivator role of CARM1 in the dysregulation of β-catenin activity in colorectal cancer cell growth and gene expression.
Ou CY; LaBonte MJ; Manegold PC; So AY; Ianculescu I; Gerke DS; Yamamoto KR; Ladner RD; Kahn M; Kim JH; Stallcup MR
Mol Cancer Res; 2011 May; 9(5):660-70. PubMed ID: 21478268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
